Sarcome de Kaposi · ligne 1 · Aucun
Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.
Contenu clinique provisoire : il ne s'agit pas d'une ordonnance. Un oncologue doit vérifier les sources originales, l'applicabilité et le statut de révision.
| Ligne thérapeutique | 1 |
|---|---|
| Voie | local_therapy |
| Régime lié | None |
| ID | IND-KAPOSI-1L-CLASSIC-LOCAL-OBSERVATION |
|---|---|
| Type | Indication |
| État | reviewed 2026-07-11 | pending_clinical_signoff |
| Maladies | DIS-KAPOSI |
| Sources | SRC-IARC-MONO-100B-2012 SRC-NCCN-SKIN-2025 |
Notes
STUB -- new TREATMENT-intent Indication for DIS-KAPOSI (v0.3 continuation), covering classic and endemic forms. Deliberately has `recommended_regimen: null` -- the disease narrative specifies only "local therapy or observation" without a preferred modality or dose, and CHARTER §8.3 prohibits inventing one; local-therapy modality selection is left to MDT/dermatology-oncology discretion pending future authoring of a dedicated local-therapy Regimen/Surgery/ RadiationCourse entity if the clinical co-leads want one formalized. INDEPENDENT REVIEW CORRECTION (2026-07-11): an earlier draft cited SRC-NCCN-SKIN-2025 with position "supports" and populated the `known_controversies[].positions[].sources` with the same id. That source documents only basal-cell/squamous-cell skin cancer (confirmed by direct inspection of its own KB record), not classic/ endemic Kaposi management -- downgraded the top-level citation to "context" and removed it from the controversy positions (no verifiable source for either side of that controversy exists in this KB, so left empty rather than fabricated). Pending two-Clinical- Co-Lead signoff (CHARTER §6.1 -- dev-mode-exempted; safe to merge as draft content, NOT...
Utilisé par
Algorithmes
ALGO-KAPOSI-1L- ALGO-KAPOSI-1L
Maladie
DIS-KAPOSI- Sarcome Kaposi